MIRAGEN THERAPEUTICS, INC. (NASDAQ:SGNL) Files An 8-K Changes in Registrant’s Certifying Accountant
Item4.01. Changes in Registrants Certifying Accountant
(a) OnMarch 24, 2017, the Audit Committee of the Board of
Directors (the Board) of Miragen Therapeutics, Inc. (the Company)
approved thedismissalofBDO USA, LLP (BDO) as the Companys
independent registered publicaccountingfirm, effective
immediately. As previously disclosed on the Companys Current
Report on Form 8-K as filed with the U.S. Securities and Exchange
Commission (the SEC) on February13, 2017, the Company has engaged
KPMG LLP as the Companys independent registered public accounting
firm for the fiscal year ended December31, 2017.
The reports of BDO on the Companys financial statements for each
of the two fiscal years ended December31, 2016, and December31,
2015, did not contain an adverse opinion or a disclaimer of
opinion, nor were they qualified or modified as to uncertainty,
audit scope oraccountingprinciples.
In connection with the audits of the Companys financial
statements for each of the two fiscal years ended December31,
2016, and December31, 2015, and the subsequent interim periods
through March24, 2017, there were no (i)disagreements (as that
term is defined in Item304(a)(1)(iv) of Regulation S-K and
related instructions) between the Company and BDO on any matter
ofaccountingprinciples or practices, financial statement
disclosure or auditing scope or procedures which, if not resolved
to the satisfaction of BDO, would have caused BDO to make
reference to the subject matter of the disagreement in their
reports, or (ii)reportable events (as that term is defined in
Item304(a)(1)(v) of Regulation S-K).
The Company provided BDO with a copy of the disclosures it is
making in this Current Report on Form 8-K and requested that BDO
furnish the Company with a letter addressed to the SEC stating
whether or not it agrees with the statements made in response to
this Item4.01, and, if not, stating the respects in which it does
not agree. BDO responded with a letter dated March24, 2017, a
copy of which is attached hereto as Exhibit16.1 to this Current
Report on Form 8-K stating that BDO agrees with the statement set
forth above.
Item5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
(e) 2017 Corporate Goals
On March24, 2017, the Board approved corporate performance goals
for the fiscal year ending December31, 2017 related to previously
approved target cash bonus percentages included in the employment
agreements between the Company and each of its executive
officers, William S. Marshall, Ph.D., Jason A. Leverone, Adam S.
Levy, and Paul D. Rubin, M.D.
to the terms of previously approved employment agreements with
each officer, each executive officer has been assigned a target
cash bonus percentage of such officers current base salary for
2017, which are set at 50% of base salary for Dr.Marshall, 35% of
base salary for Mr.Leverone, 40% of base salary for Mr.Levy, and
40% of base salary for Dr.Rubin. To receive any portion of his
cash bonus award, to the employment agreements, each officer must
be employed by the Company on the date any such bonuses are
payable. The amounts payable to each officer are subject to
review and adjustment in the sole discretion of the Board or the
Companys compensation committee and will be weighted for each
officer based on the Boards determination of the corporate goals.
The approved corporate goals, which may be updated at the Boards
discretion during 2017, include:
|
goals related to defining a development and registration path for, as well as goals related to expansion indications of MRG-106, the Companys clinical product candidate for the treatment of certain cancers; |
|
goals related to the clinical advancement of MRG-201, the Companys clinical product candidate for the treatment of pathological fibrosis; |
|
goals related to the development of the Companys pre-clinical product candidate pipeline; and |
|
finance and business development goals, including collaboration objectives. |
Item9.01 Financial Statements and Exhibits
| (d) |
Reference is made to the Exhibit Index included with this Current Report on Form 8-K. |
About MIRAGEN THERAPEUTICS, INC. (NASDAQ:SGNL)
miRagen Therapeutics Inc., formerly Signal Genetics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of micro-ribonucleic acid (RNA)-targeted therapies. Its lead product candidates, MRG-106 and MRG-201, are in Phase I clinical trials. Its therapeutic areas of focus include cancer, pathologic fibrosis, neuro-inflammatory and cardiovascular diseases. Its clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in several blood cancers. The Company’s clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for miR-29, which is found at abnormally low levels in a range of pathological fibrotic conditions, including cardiac, renal, hepatic and pulmonary fibrosis, as well as systemic sclerosis. In addition to its clinical programs, it is developing a pipeline of pre-clinical product candidates. MIRAGEN THERAPEUTICS, INC. (NASDAQ:SGNL) Recent Trading Information
MIRAGEN THERAPEUTICS, INC. (NASDAQ:SGNL) closed its last trading session 00.00 at 12.30 with 38,761 shares trading hands.
